Pharma BD Deal Intelligence
Luminex Corporation acquired GenturaDx in a $50 million transaction to expand its capabilities in molecular diagnostics and laboratory testing technologies for…
signed on its behalf by the undersigned hereunto duly authorized.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Luminex Corporation acquired GenturaDx for $50 million in cash to expand its molecular diagnostics platform, adding GenturaDx's sample-to-answer real-time PCR and MultiCode-RTx chemistry.
The customizable/flex-report respiratory pathogen panel market splits into three MOA classes a commercial lead should size by panel-report flexibility. Flex-reporting cartridge PCR with on-demand target selection (DiaSorin LIAISON PLEX Respiratory Flex Assay, FDA-cleared K233232): differentiated positioning allowing labs to report a configurable subset of up to ~22 viral/bacterial targets per patient, addressing payer scrutiny of full-panel CPT 87633. Fixed-panel multiplex nested-PCR syndromic (BioFire Respiratory 2.1 plus Panel by bioMerieux, FDA-cleared, 22 fixed targets; Roche/GenMark ePlex Respiratory Pathogen Panel 2, FDA-cleared, 21 fixed targets): dominant installed-base but locked full-panel reporting constrains reflex-testing strategies. Narrower fixed-panel sample-to-answer (Cepheid Xpert Xpress CoV-2/Flu/RSV plus, FDA-cleared, 4 targets; QIAstat-Dx Respiratory SARS-CoV-2 Panel, FDA-cleared, 21 targets): split between ED-focused short panels and mid-breadth hospital panels. Mid-plex real-time PCR (Hologic Panther Fusion SARS-CoV-2/Flu/RSV; Abbott Alinity m Resp-4-Plex): high-throughput central-lab positioning. Commercial threat for LIAISON PLEX Respiratory Flex: the flex-reporting architecture is the genuine differentiator against BioFire FilmArray's fixed-panel dominance — adoption hinges on payer policies rewarding selective reporting and on AMP/CAP guidance favoring flex workflows over full-panel defaults. BioFire and ePlex retain the reimbursement-per-cartridge advantage for routine respiratory workup.
The CYP2C19 pharmacogenomic IVD market is fragmented across three MOA classes that a commercial lead should size distinctly. Bead-based multiplex PCR (Luminex xTAG CYP2C19 Kit v3): FDA-cleared as a laboratory-developed test component, historically run on the xMAP/MAGPIX platform — incumbent position in reference laboratories but dependent on moderate-complexity CLIA infrastructure. Array-based hybridization (Roche AmpliChip CYP450 Test): the first FDA-cleared CYP2C19/2D6 genotyping assay (K042259, 2005), cleared for the Affymetrix GeneChip platform — commercially retired by Roche but still defines the incumbent reference claim set. Cartridge-based rapid PCR (Spartan Bioscience Spartan RX CYP2C19): FDA-cleared point-of-care system delivering results in ~60 minutes from buccal swab, positioned for cath-lab clopidogrel guidance; validated in the TAILOR-PCI and RAPID GENE programs. Real-time PCR allele-specific (Thermo Fisher TaqMan CYP2C19 assays; Autogenomics INFINITI CYP2C19): used as LDT components across AmeriPath/Quest/LabCorp reference pipelines. Commercial threat for xTAG CYP2C19: market is structurally shifting from central-lab multiplex panels toward rapid, single-gene, cath-lab-embedded cartridge workflows (Spartan, GenMark ePlex), compressing Luminex's pricing power in clopidogrel-guided PCI settings. Sales disclosure is limited; Luminex assay revenue is reported only at segment level in DiaSorin filings.
The central-lab molecular diagnostic platform market splits into three MOA classes a commercial lead should size by throughput tier. Random-access direct-amplification real-time PCR (DiaSorin/Luminex LIAISON MDX, FDA-cleared platform; Hologic Panther Fusion, FDA-cleared): mid-throughput positioning, >2,700 Panther systems installed per Hologic FY2023 10-K. High-throughput automated real-time PCR (Roche cobas 6800/8800 Systems, FDA-cleared; Abbott Alinity m, FDA-cleared): large reference-lab and blood-screening dominance, cobas 8800 runs up to 960 results/8 hours per Roche IR. Sample-to-answer cartridge PCR (Cepheid GeneXpert Infinity/Xpert family; BioFire FilmArray Torch by bioMerieux; QIAstat-Dx by QIAGEN): on-demand hospital workflow, GeneXpert installed-base >30,000 globally per Danaher segment commentary. Isothermal amplification platforms (Abbott ID NOW): CLIA-waived point-of-care. Next-generation sequencing platforms (Illumina NextSeq Dx; Thermo Fisher Ion Torrent Genexus): emerging oncology companion-diagnostics pathway, not yet standard for ID menu. Commercial threat for LIAISON MDX: mid-throughput is a squeezed tier — Panther dominates reference-lab scale while GeneXpert dominates hospital on-demand. DiaSorin/Luminex positioning depends on bundled menu (Simplexa direct-amplification kits) and cost-per-result in community hospital central labs. DiaSorin reports diagnostics revenue at segment level only; LIAISON MDX standalone share is not disclosed.
The sample-to-answer molecular diagnostic platform market splits into three MOA classes a commercial lead should size by menu scope. Gold-nanoparticle array detection (Luminex VERIGENE System, FDA-cleared; now succeeded by LIAISON PLEX): syndromic hospital-lab positioning with FDA-cleared Bloodstream Infection (BC-GN, BC-GP), Enteric Pathogens, and Respiratory Pathogens panels. Multiplex nested-PCR syndromic cartridges (BioFire FilmArray by bioMerieux, FDA-cleared; QIAstat-Dx Analyzer by QIAGEN, FDA-cleared): dominant US hospital infectious-disease syndromic position — BioFire installed in >9,000 US institutions per Danaher segment filings. Real-time PCR cartridge (Cepheid GeneXpert Infinity/Xpress family, FDA-cleared): on-demand single- or small-multiplex hospital/ED positioning, installed-base >30,000 globally. Electrowetting digital microfluidics (GenMark/Roche ePlex): syndromic Respiratory and Bloodstream panels, FDA-cleared — direct VERIGENE competitor in hospital sepsis workup. Commercial threat for VERIGENE: BioFire's 2019 blood-culture identification panel (BCID2) and ePlex BCID-GP/GN panels compressed VERIGENE's differentiated sepsis positioning, driving DiaSorin to sunset VERIGENE in favor of the successor LIAISON PLEX platform per DiaSorin FY2023 annual report disclosures. Share in hospital-lab syndromic sepsis has shifted materially to BioFire since 2020.
The differential respiratory virus syndromic-panel IVD market segments into three MOA classes a commercial lead should size by panel breadth. Multiplex nested-PCR syndromic panels (BioFire FilmArray Respiratory 2.1/2.1 plus by bioMerieux, FDA-cleared, 22 targets; GenMark/Roche ePlex Respiratory Pathogen Panel 2, FDA-cleared, 21 targets): hospital-lab standard of care for full-workup respiratory panels — BioFire is installed in >9,000 US hospitals per Danaher segment filings. Direct-amplification real-time PCR targeted panels (DiaSorin/Luminex Simplexa COVID-19 and Flu A/B Direct on LIAISON MDX; Hologic Panther Fusion Flu A/B/RSV/SARS-CoV-2): narrower panel, random-access, cost-competitive central-lab positioning. Bead-based multiplex PCR (Luminex NxTAG Respiratory Pathogen Panel on MAGPIX, FDA-cleared, 19 targets): reference-lab-oriented, batched workflow. Cartridge on-demand PCR (Cepheid Xpert Xpress CoV-2/Flu/RSV plus): 4-plex, ED-focused. Isothermal CLIA-waived (Abbott ID NOW, 3-plex): outpatient. Commercial threat for Simplexa: narrow-panel direct-PCR is squeezed between broader syndromic panels (BioFire/ePlex) capturing reimbursement under CPT 87633 (5-plus target panel, ~$416) and point-of-care cartridges capturing ED volume. DiaSorin differentiation rests on LIAISON MDX consolidation with other menu items and lower consumables cost in community hospitals.
The multiplex bead-based molecular analysis platform market splits into three MOA classes a commercial lead should size by application (IVD vs. research/protein). Fluorescent bead-based multiplex (Luminex MAGPIX, FDA-cleared platform; Luminex 200/FlexMAP 3D for research): xMAP technology hosts >100 FDA-cleared IVD kits and >1,000 Luminex-partner LDTs — dominant installed-base in reference labs and CLIA molecular departments. Flow-cytometry-based multiplex (BD CBA/FACS bead arrays; Thermo Fisher ProcartaPlex on Bio-Plex): primarily research-use cytokine/protein panels, non-IVD positioning. Digital array multiplex (Fluidigm Biomark HD; Standard BioTools IFC chips): low-throughput high-multiplex research, emerging IVD pathway. Proximity-extension assay (Olink Explore/Target): research proteomics, non-directly-competitive in IVD. NGS amplicon multiplexing (Illumina AmpliSeq panels; Thermo Fisher Ion AmpliSeq): high-content research and oncology companion diagnostics, encroaching on MAGPIX infectious-disease multiplex. Commercial threat for MAGPIX: the platform's installed-base and menu are defensible in mid-throughput reference labs, but NGS panel economics are compressing multi-analyte research revenue, and syndromic cartridge platforms (BioFire FilmArray, Roche ePlex) have captured the hospital clinical-multiplex tier. DiaSorin disclosed in its FY2023 annual report that it is transitioning the Luminex franchise toward LIAISON-branded IVD workflows rather than defending MAGPIX standalone menu growth.
The next-generation syndromic molecular testing platform market splits into three MOA classes a commercial lead should size by menu depth. Automated sample-to-answer cartridge PCR with array detection (DiaSorin LIAISON PLEX, FDA-cleared; successor to VERIGENE): flex-panel architecture allowing targeted reporting from a full-cartridge result, FDA-cleared Respiratory Flex, Bloodstream Gram-negative, Gram-positive and Yeast panels. Multiplex nested-PCR syndromic cartridges (BioFire FilmArray Torch by bioMerieux, FDA-cleared; QIAstat-Dx Analyzer by QIAGEN, FDA-cleared): entrenched US hospital-lab syndromic standard-of-care — BioFire installed-base >9,000 US hospitals per Danaher segment filings. Electrowetting digital microfluidics (GenMark/Roche ePlex, FDA-cleared): Respiratory Pathogen Panel 2 and BCID-GP/GN, Roche-owned since 2021. On-demand real-time PCR (Cepheid GeneXpert Infinity, FDA-cleared): single- to small-multiplex on-demand workflow, >30,000 systems installed. Commercial threat for LIAISON PLEX: BioFire and Roche ePlex own hospital-lab syndromic mindshare and the CPT 87633 full-panel reimbursement path. LIAISON PLEX's differentiated Flex targeted-reporting architecture must demonstrate cost-per-reportable-result advantage — DiaSorin's FY2023 report cites PLEX launch as a multi-year conversion of the VERIGENE installed-base rather than net-new share capture. DiaSorin does not disclose PLEX standalone revenue.
The HSV-1/2 molecular IVD market splits into three MOA classes a commercial lead should size by specimen (CSF encephalitis vs. anogenital swab). Direct-amplification real-time PCR (DiaSorin/Luminex Simplexa HSV 1 & 2 Direct, FDA-cleared K121345, for cutaneous/mucocutaneous lesions; Roche cobas HSV 1 and 2 Test on cobas 6800/8800, FDA-cleared, for anogenital specimens): central-lab workflow, no extraction step for Simplexa — positioning on turnaround time. Meningitis/encephalitis syndromic panels (BioFire FilmArray Meningitis/Encephalitis Panel by bioMerieux, FDA-cleared, HSV-1/HSV-2 among 14 targets; QIAstat-Dx Meningitis/Encephalitis Panel by QIAGEN): dominant CSF workup pathway in US hospital labs — threat is that CSF HSV testing is increasingly subsumed by the syndromic panel standard-of-care. Dedicated multiplex real-time PCR (Altona AltoStar HSV PCR Kit 1.5, CE-IVD; Diagenode HSV 1 & 2 Quant kit): European transplant/lesion monitoring. Laboratory-developed tests (ARUP, Quest HSV by PCR): historical CSF encephalitis standard. Commercial threat for Simplexa HSV 1 & 2 Direct: FilmArray M/E Panel has consolidated CSF volume into syndromic workflows, relegating single-pathogen HSV PCR largely to the anogenital lesion market where Roche cobas holds scale advantage.
Congenital CMV (cCMV) molecular diagnostics split into three MOA classes that a commercial lead should segment by sample type and workflow. Real-time PCR direct-amplification kits (DiaSorin/Luminex Simplexa Congenital CMV Direct): FDA-cleared (K212683, 2022) for saliva swab detection, run on LIAISON MDX — first FDA-cleared cCMV newborn screening assay, positioning in hospital newborn-nursery workflows. Cartridge-based random-access PCR (Altona Diagnostics AltoStar CMV PCR Kit 1.5; Roche cobas CMV Test on cobas 6800/8800): EMA CE-IVD and FDA-cleared respectively for plasma quantitation — dominant in transplant viral-load monitoring but not cleared for saliva/urine newborn screening. Laboratory-developed tests (Viracor Eurofins CMV qPCR; ARUP Laboratories CMV by PCR): the historical standard of care for cCMV screening using in-house real-time PCR on Roche LightCycler or ABI 7500 platforms — no unified FDA clearance, CLIA-only. Digital-PCR/next-gen entrants (Bio-Rad QX200 ddPCR CMV assays): research-use-only, emerging for low-viral-load confirmation. Commercial threat for Simplexa: first-mover FDA clearance on saliva gives DiaSorin a pricing and EHR-integration moat in universal newborn CMV screening — a CDC-supported use case — while reference-lab LDTs compete on cost and plasma reflex testing. CMS screening adoption is the key volume driver.
The Flu/RSV/SARS-CoV-2 4-plex respiratory IVD market splits into three MOA classes that a commercial lead should size by site-of-care. Sample-to-answer cartridge PCR (Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV plus, FDA-cleared; BioFire Respiratory 2.1 Panel by bioMerieux, FDA-cleared): dominant hospital/ED position with GeneXpert installed-base >30,000 systems globally per Danaher IR filings — key share-holder in high-acuity settings. Direct-amplification random-access PCR (DiaSorin/Luminex LIAISON NES Flu A/B, RSV, and COVID-19 Assay on LIAISON MDX; Hologic Panther Fusion SARS-CoV-2/Flu A/B/RSV): central-lab batching positioning, Hologic Panther installed-base >2,700 per Hologic 10-K — threat is lower unit cost and higher throughput. CLIA-waived point-of-care (Abbott ID NOW COVID-19/Flu A&B/RSV isothermal; Roche cobas liat SARS-CoV-2 & Influenza A/B): retail-pharmacy and urgent-care positioning, Abbott ID NOW runs 13-minute isothermal amplification. Antigen-based lateral flow (Quidel QuickVue; BD Veritor) occupies a distinct MOA class with lower sensitivity, not directly competitive at PCR performance. Commercial threat for LIAISON NES: Cepheid and BioFire hold hospital-lab standard-of-care; DiaSorin must compete on menu breadth and cost-per-reportable-result in community-hospital and reference-lab tiers.
Transaction completed based on available records. Limited structured data available for this deal.
Limited public data available for this transaction. Assessment based on available corporate records and SEC filings.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GenturaDx / LUMINEX CORP (this deal) | 2012 | $50M | 48 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| bioMerieux SA / BioFire Diagnostics Inc. | 2013 | $485M | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2012 deals · Infectious Disease deals